NCT07009899尚未招募2 期
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Overall Response Rate
研究概览
简要总结
This is a single-center, single-arm, phase 2 study designed to evaluate the efficacy and safety of linvoseltamab in multiple myeloma (MM) patients who relapsed following BCMA CAR T-cell therapy, whether standard of care or investigational.
详细描述
This is a single-center, single-arm, phase 2 study designed to evaluate the efficacy and safety of linvoseltamab in multiple myeloma (MM) patients who relapsed following BCMA CAR T-cell therapy, whether standard of care or investigational. The primary objective is to assess overall response rate (ORR) in patients treated with linvoseltamab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status criteria of 0-
- •Received any standard of care or investigational BCMA CAR T-cell therapy as their last line of therapy ≥ 6 months prior to enrollment.
- •a. Note: Up to 15% of patients who are < 6 months out from their standard of care of investigational BCMA CAR T-cell therapy will be included in the study as long as i) their bone marrow biopsy sample tests positive for BCMA expression by immunohistochemistry and ii) they have stem cells available for a stem cell boost therapy prior to linvoseltamab administration.
- •Must have measurable disease for response assessment as per the IMWG response assessment criteria.
- •a. Note: if a patient does not have measurable serum M or free light chain, evidence of measurable disease by imaging is acceptable (e.g., extramedullary disease, new lesions).
- •Adequate hepatic function as defined below:
- •Total bilirubin ≤ 1.5 x the upper limit of the normal range (ULN).
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN.
- •Ability to understand a written informed consent document, and the willingness to sign it.
排除标准
- •Previously on a BCMA-directed therapy other than BCMA CAR T-cell therapy (e.g., BCMA bispecific antibody, BCMA antibody drug conjugate) or T cell engaging therapy (e.g., GPRC5D bispecific antibody, GPRC5D CAR T-cell therapy).
- •History of neurodegenerative condition, Central Nervous System (CNS) movement disorder, or patients with a history of seizure within 12 months prior to study enrollment.
- •Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
- •Prior organ transplant requiring immunosuppressive therapy.
- •Known to be human immunodeficiency virus (HIV) positive.
- •Known to have hepatitis A, B, or C active infection.
- •Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
- •Concurrent hematologic or non-hematologic malignancy requiring treatment (other than multiple myeloma and secondary amyloidosis).
- •Cardiac syncope, uncompensated New York Heart Association (NYHA) Class 3 or 4 congestive heart failure, myocardial infarction within the previous six months, unstable angina pectoris, clinically significant repetitive ventricular arrhythmias despite antiarrhythmic treatment, cardiac ejection fraction < 40% by echocardiogram or multi-gated acquisition (MUGA) scan, severe orthostatic hypotension, or clinically important autonomic disease.
- •Major surgery within 14 days prior to start of study treatment (Note: vertebroplasty and kyphoplasty are not considered major surgery).
- •Infection requiring systemic antibiotic therapy or other serious infection within 14 days prior to start of study treatment.
- •Active treatment in other clinical trials, including those where a subject received an investigational drug within 30 days or five half-lives of the investigational drug prior to start of study treatment, whichever is longer.
- •Any clinically significant, uncontrolled medical conditions that, in the investigator's opinion, would expose the subject to excessive risk or may interfere with compliance or interpretation of the study results.
- •Pregnant or breastfeeding women.
- •Women of childbearing potential (WOCBP) or sexually active men who are unwilling to practice highly effective contraception prior to the start of study therapy, during the study, and for at least 6 months after the last dose of the study drug.
- •WOCBP are defined as women who are fertile following menarche until becoming postmenopausal (defined as no menses for 12 months without an alternative medical cause), unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.
- •Male study participants with WOCBP partners are required to use condoms unless they are vasectomized or practice sexual abstinence. Male study participants should not donate sperm during the study, and for at least 6 months after the last dose
- •Highly effective contraceptive measures include stable use of combined (estrogen and progestogen-containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated two or more menstrual cycles prior to screening; intrauterine device; intrauterine hormone-releasing system; bilateral tubal ligation; vasectomized partner (provided that the vasectomized partner is the sole sexual partner of the WOCBP study participant); and or sexual abstinence.
研究组 & 干预措施
Linvoseltamab Administration
Experimental
Linvoseltamab intravenous (IV) will be initially administered to all patients as a step-up dosing regimen during the first two weeks of Cycle 1 (Weeks 1 and 2; 5 mg on Cycle 1 Day 1 and 25 mg on Cycle 1 Day 8) in an inpatient setting. Starting with Cycle 1 Day 15 (Week 3), linvoseltamab 200 mg will be administered once a week until the end of Cycle 3 (Week 12) followed by once every two weeks (Days 1 and 15) during Cycles 4 through 6 (Weeks 13 through 24). From Cycle 7 Day 1 (Week 25) until disease progression, linvoseltamab 200 mg will be administered once every four weeks.
干预措施: Linvoseltamab (Drug)
结局指标
主要结局
Overall Response Rate
时间窗: Up to 15 months
This is the number of subjects who have a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria.
次要结局
未报告次要终点
研究者
Binod Dhakal
Associate Professor
Medical College of Wisconsin
研究点 (1)
Loading locations...
相似试验
尚未招募
早期 1 期
Study of SYS6020 in BCMA-positive Multiple MyelomaMultiple MyelomaNCT06359509Union Hospital, Tongji Medical College, Huazhong University of Science and Technology10
招募中
1 期
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia GravisMyasthenia GravisNCT06688435CSPC ZhongQi Pharmaceutical Technology Co., Ltd.60
进行中（未招募）
1 期
Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple MyelomaRefractory Multiple MyelomaRelapsed Multiple MyelomaNCT05577000Thomas Martin, MD5
已完成
2 期
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple MyelomaMultiple MyelomaNCT05032820Medical College of Wisconsin40
招募中
1 期
Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary InfiltrationNCT07003555Beijing GoBroad Hospital18